Effect of concomitant medications with immune-modulatory properties on the outcomes of patients with advanced cancer treated with immune checkpoint inhibitors: development and validation of a novel prognostic index

Efficacy of chemotherapy and atezolizumab in patients with non-small-cell lung cancer receiving antibiotics and proton pump inhibitors: pooled post hoc analyses of the OAK and POPLAR trials

(2020) M. Chalabi et al.   ANNALS OF ONCOLOGY

Association of Steroids use with Survival in Patients Treated with Immune Checkpoint Inhibitors: A Systematic Review and Meta-Analysis

(2020) Fausto Petrelli et al.   Cancers

Inferring the role of the microbiome on survival in patients treated with immune checkpoint inhibitors: causal modeling, timing, and classes of concomitant medications

(2020) Daniel Spakowicz et al.   BMC CANCER

Clinicopathologic correlates of first-line pembrolizumab effectiveness in patients with advanced NSCLC and a PD-L1 expression of ≥ 50%

(2020) Alessio Cortellini et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Another side of the association between body mass index (BMI) and clinical outcomes of cancer patients receiving programmed cell death protein-1 (PD-1)/ Programmed cell death-ligand 1 (PD-L1) checkpoint inhibitors: A multicentre analysis of immune-related adverse events

(2020) Alessio Cortellini et al.   EUROPEAN JOURNAL OF CANCER

Polypharmacy as a prognostic factor in older patients with advanced non-small-cell lung cancer treated with anti-PD-1/PD-L1 antibody-based immunotherapy

(2020) Taiki Hakozaki et al.   JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY

The Prognostic Role of High Blood Cholesterol in Advanced Cancer Patients Treated With Immune Checkpoint Inhibitors

(2020) Fabiana Perrone et al.   JOURNAL OF IMMUNOTHERAPY

The Pivotal Role of the Dysregulation of Cholesterol Homeostasis in Cancer: Implications for Therapeutic Targets

(2020) Etienne Ho Kit Mok et al.   Cancers

Concomitant medications and immune checkpoint inhibitor therapy for cancer: causation or association?

(2020) Nadiya Hussain et al.   Human Vaccines & Immunotherapeutics

A multicenter study of body mass index in cancer patients treated with anti-PD-1/PD-L1 immune checkpoint inhibitors: when overweight becomes favorable

(2019) Alessio Cortellini et al.   Journal for ImmunoTherapy of Cancer

The Urinary Microbiome and Anticancer Immunotherapy: The Potentially Hidden Role of Unculturable Microbes

(2019) Melissa Bersanelli et al.   Targeted Oncology

Antibiotics-Driven Gut Microbiome Perturbation Alters Immunity to Vaccines in Humans

(2019) Thomas Hagan et al.   CELL

Immune Checkpoint Inhibitor Outcomes for Patients With Non–Small-Cell Lung Cancer Receiving Baseline Corticosteroids for Palliative Versus Nonpalliative Indications

(2019) Biagio Ricciuti et al.   JOURNAL OF CLINICAL ONCOLOGY

Association of Prior Antibiotic Treatment With Survival and Response to Immune Checkpoint Inhibitor Therapy in Patients With Cancer

(2019) David J. Pinato et al.   JAMA Oncology

The Impact of Nonsteroidal Anti‐Inflammatory Drugs, Beta Blockers, and Metformin on the Efficacy of Anti‐PD‐1 Therapy in Advanced Melanoma

(2019) Daniel Y. Wang et al.   ONCOLOGIST

Negative association of antibiotics on clinical activity of immune checkpoint inhibitors in patients with advanced renal cell and non-small-cell lung cancer

(2018) L Derosa et al.   ANNALS OF ONCOLOGY

The Influence of the Gut Microbiome on Cancer, Immunity, and Cancer Immunotherapy

(2018) Vancheswaran Gopalakrishnan et al.   CANCER CELL

Clinical and hematologic parameters address the outcomes of non-small-cell lung cancer patients treated with nivolumab

(2018) Francesco Facchinetti et al.   Immunotherapy

Chronic glucocorticoid treatment induced circadian clock disorder leads to lipid metabolism and gut microbiota alterations in rats

(2018) Tao Wu et al.   LIFE SCIENCES

Efficacy of metformin in combination with immune checkpoint inhibitors (anti-PD-1/anti-CTLA-4) in metastatic malignant melanoma

(2018) Muhammad Zubair Afzal et al.   Journal for ImmunoTherapy of Cancer

Efficacy of PD-1 & PD-L1 inhibitors in older adults: a meta-analysis

(2018) Rawad Elias et al.   Journal for ImmunoTherapy of Cancer

Impact of Baseline Steroids on Efficacy of Programmed Cell Death-1 and Programmed Death-Ligand 1 Blockade in Patients With Non–Small-Cell Lung Cancer

(2018) Kathryn C. Arbour et al.   JOURNAL OF CLINICAL ONCOLOGY

LBA2Proton pump inhibitors negatively impact survival of PD-1 inhibitor based therapies in metastatic melanoma patients

(2018) K Homicsko et al.   ANNALS OF ONCOLOGY

The appropriate use of proton pump inhibitors (PPIs): Need for a reappraisal

(2017) Vincenzo Savarino et al.   European Journal of Internal Medicine

Gut microbiome influences efficacy of PD-1–based immunotherapy against epithelial tumors

(2017) Bertrand Routy et al.   SCIENCE

Prognostic value of smoking status in non-small-cell lung cancer patients treated with immune checkpoint inhibitors: a meta-analysis

(2017) Jung Han Kim et al.   Oncotarget

Regression coefficient–based scoring system should be used to assign weights to the risk index

(2016) Hemalkumar B. Mehta et al.   JOURNAL OF CLINICAL EPIDEMIOLOGY

Effects of commonly used chronic medications on the outcomes of ipilimumab therapy in patients with metastatic melanoma

(2016) Jarrett J. Failing et al.   MELANOMA RESEARCH

Proton pump inhibitors alter the composition of the gut microbiota

(2015) Matthew A Jackson et al.   GUT

Using Corticosteroids to Reshape the Gut Microbiome

(2015) Edmond Y. Huang et al.   INFLAMMATORY BOWEL DISEASES

The Impact of Proton Pump Inhibitors on the Human Gastrointestinal Microbiome

(2014) Daniel E. Freedberg et al.   CLINICS IN LABORATORY MEDICINE

Short-Term Antibiotic Treatment Has Differing Long-Term Impacts on the Human Throat and Gut Microbiome

(2010) Hedvig E. Jakobsson et al.   PLoS One

New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)

(2008) E.A. Eisenhauer et al.   EUROPEAN JOURNAL OF CANCER